Core Points - Transgene has appointed Emmanuelle Quilès as an independent Director to its Board of Directors, succeeding Philippe Archinard, who is retiring [1][3] - Emmanuelle Quilès brings over 25 years of experience in strategic leadership roles within the global pharmaceutical industry, previously serving as Worldwide Vice President at Janssen Global Commercial Strategy Organization [2][5] - The appointment is effective from July 9, 2025, and Quilès will serve the remainder of Archinard's term until the 2026 Annual Shareholders' Meeting [3] Company Overview - Transgene is a biotechnology company focused on designing and developing virus-based immunotherapies for cancer treatment, with a portfolio that includes TG4050, TG4001, BT-001, and TG6050 [8] - The company utilizes its myvac® platform for individualized therapeutic vaccines and the Invir.IO® platform for multifunctional oncolytic viruses [9][10] - Transgene's clinical-stage programs are aimed at providing targeted immunotherapies, with a focus on precision medicine [8][9]

Core Insights - Transgene will present two-year disease-free survival data from the Phase I part of the TG4050 trial at ASCO 2025 [1][3] - TG4050 is an individualized neoantigen therapeutic cancer vaccine developed using Transgene's myvac® platform and NEC's AI capabilities [2][10] - The Phase I/II trial is focused on HPV-negative head and neck cancers, with the Phase II part currently enrolling patients internationally [3][12] Company Overview - Transgene is a biotechnology company specializing in virus-based immunotherapies for cancer treatment [5][7] - The company’s lead asset, TG4050, is the first individualized therapeutic vaccine based on the myvac® platform [5][10] - Transgene is also developing other viral vector-based immunotherapies, including TG4001 for HPV-positive cancers [7] Clinical Trial Details - The Phase I/II trial evaluates TG4050 as a single agent in the adjuvant treatment of HPV-negative head and neck cancers [3][12] - The trial includes a randomized study design with 32 evaluable patients in the Phase I part [12] - The Phase II extension is currently enrolling patients, indicating ongoing development and potential for future data [3][12] Presentation and Recognition - The rapid oral presentation at ASCO will take place on June 1, 2025, highlighting the clinical data and collaborative efforts in the trial [1][3] - Transgene's findings on TG4050 were selected for presentation among numerous high-quality submissions, reflecting the significance of their work [3]

Core Points - The Combined Ordinary and Extraordinary General Meeting of Transgene's shareholders took place on May 15, 2025, where various resolutions were voted on and approved [1][2] - The meeting resulted in the renewal of the terms of office for several Board Members, maintaining a diverse and independent Board composition [3][4] - A share capital reduction was approved, decreasing the par value of shares from €0.50 to €0.30, along with the delegation of authority for a potential reverse stock split [5] Company Overview - Transgene is a biotechnology company focused on developing targeted immunotherapies for cancer treatment, with a portfolio that includes viral vector-based immunotherapeutics [7] - The lead asset, TG4050, is an individualized therapeutic vaccine aimed at head and neck cancers, showcasing the company's innovative approach to precision medicine [8] - Transgene utilizes its proprietary Invir.IO® platform to engineer multifunctional oncolytic viruses, enhancing its capabilities in viral vector technology [9]